losartan (drug)

ApprovedUNKNOWN

1 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Alcoholic Liver Cirrhosis

Conditions

Alcoholic Liver Cirrhosis, Ascites

Trial Timeline

Sep 1, 2005 → Sep 1, 2011

NCT ID

NCT00239096

About losartan (drug)

losartan (drug) is a approved stage product being developed by Lundbeck for Alcoholic Liver Cirrhosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00239096. Target conditions include Alcoholic Liver Cirrhosis, Ascites.

What happened to similar drugs?

0 of 10 similar drugs in Alcoholic Liver Cirrhosis were approved

Approved (0) Terminated (3) Active (7)

🔄IVA337 + PlaceboInventivaPhase 3

🔄GODEX + PlaceboCelltrionPhase 3

❌SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3

🔄Semaglutide + PlaceboNovo NordiskPhase 3

🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3

🔄Placebo + ResmetiromMadrigal PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00239096	Approved	UNKNOWN	Sep 1, 2005	Sep 1, 2011	Alcoholic Liver Cirrhosis

Competing Products

20 competing products in Alcoholic Liver Cirrhosis

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
Lanifibranor	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
GODEX + Placebo	Celltrion	Phase 3	47
Colesevelam Hcl	Daiichi Sankyo	Phase 2	35
ASP9831 + Placebo	Astellas Pharma	Phase 2	35
Tirzepatide + Placebo	Eli Lilly	Phase 2	35
AZD9550 + AZD9550 + Placebo	AstraZeneca	Phase 1	29
AZD2693	AstraZeneca	Phase 1	29
placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo	AstraZeneca	Phase 2	35
AZD4831	AstraZeneca	Phase 2	35
AZD2693	AstraZeneca	Phase 2	35
AZ compound	AstraZeneca	Phase 2	27
cotadutide solution for injection	AstraZeneca	Phase 1	29
Cotadutide + Cotadutide-placebo + Moxifloxacin + Moxifloxacin-placebo	AstraZeneca	Phase 1	21